High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center
- PMID: 22902776
- PMCID: PMC3891826
- DOI: 10.1016/j.cgh.2012.08.017
High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center
Abstract
Background & aims: There are limited data on the prevalence or predictors of antibiotic-resistant bacterial infections (AR-BI) in hospitalized patients with cirrhosis in North America. Exposure to systemic antibiotics is a risk factor for AR-BI; however, little is known about the effects of the increasingly used oral nonabsorbed antibiotics.
Methods: We analyzed data from patients with cirrhosis and bacterial infections hospitalized in a liver unit at a US hospital between July 2009 and November 2010. Multivariate logistic regression was used to determine predictors of AR-BI. Data were analyzed on the first bacterial infection of each patient (n = 115), and a sensitivity analysis was performed on all infectious episodes per patient (n = 169).
Results: Thirty percent of infections were nosocomial. Urinary tract infections (32%) and spontaneous bacterial peritonitis (24%) were most common. Of the 70 culture-positive infections, 33 (47%) were found to be antibiotic resistant (12 were vancomycin-resistant Enterococci, 9 were extended-spectrum β-lactamase-producing Enterobacteriaceae, 7 were quinolone-resistant gram-negative rods, and 5 were methicillin-resistant Staphylococcus aureus). Exposure to systemic antibiotics within 30 days before infection was associated independently with AR-BI, with an odds ratio (OR) of 13.5 (95% confidence interval [CI], 2.6-71.6). Exposure to only nonabsorbed antibiotics (rifaximin) was not associated with AR-BI (OR, 0.4; 95% CI, 0.04-2.8). In a sensitivity analysis, exposure to systemic antibiotics within 30 days before infection and nosocomial infection was associated with AR-BI (OR, 5.2; 95% CI, 1.5-17.7; and OR, 4.2; 95% CI, 1.4-12.5, respectively).
Conclusions: The prevalence of AR-BI is high in a US tertiary care transplant center. Exposure to systemic antibiotics within 30 days before infection (including those used for prophylaxis of spontaneous bacterial peritonitis), but not oral nonabsorbed antibiotics, is associated with development of an AR-BI.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.J Hepatol. 2019 Mar;70(3):398-411. doi: 10.1016/j.jhep.2018.10.027. Epub 2018 Nov 2. J Hepatol. 2019. PMID: 30391380
-
Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms.J Clin Gastroenterol. 2018 Aug;52(7):648-654. doi: 10.1097/MCG.0000000000000964. J Clin Gastroenterol. 2018. PMID: 29176351
-
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.Hepatology. 2012 May;55(5):1551-61. doi: 10.1002/hep.25532. Epub 2012 Apr 4. Hepatology. 2012. PMID: 22183941
-
New antibiotic strategies in patients with cirrhosis and bacterial infection.Expert Rev Gastroenterol Hepatol. 2015;9(12):1495-500. doi: 10.1586/17474124.2015.1100075. Epub 2015 Oct 14. Expert Rev Gastroenterol Hepatol. 2015. PMID: 26465070 Review.
-
Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.Am J Med. 1996 Jun 24;100(6A):3S-12S. doi: 10.1016/s0002-9343(96)00102-7. Am J Med. 1996. PMID: 8678095 Review.
Cited by
-
Improvement of gut microbiome and intestinal permeability following splenectomy plus pericardial devascularization in hepatitis B virus-related cirrhotic portal hypertension.Front Immunol. 2022 Sep 8;13:941830. doi: 10.3389/fimmu.2022.941830. eCollection 2022. Front Immunol. 2022. PMID: 36159870 Free PMC article.
-
Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure.BMC Infect Dis. 2022 Jan 4;22(1):23. doi: 10.1186/s12879-021-07018-2. BMC Infect Dis. 2022. PMID: 34983426 Free PMC article.
-
Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis.Sci Rep. 2017 Sep 13;7(1):11482. doi: 10.1038/s41598-017-11587-1. Sci Rep. 2017. PMID: 28904387 Free PMC article.
-
Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia.World J Gastroenterol. 2016 Apr 21;22(15):4049-56. doi: 10.3748/wjg.v22.i15.4049. World J Gastroenterol. 2016. PMID: 27099449 Free PMC article.
-
Ascitic fluid infection in children with liver disease: time to change empirical antibiotic policy.Hepatol Int. 2020 Jan;14(1):138-144. doi: 10.1007/s12072-019-09968-x. Epub 2019 Jul 9. Hepatol Int. 2020. PMID: 31290071
References
-
- Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multi-organ failure in cirrhosis. Semin Liver Dis. 2008;28:26–42. - PubMed
-
- Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–148. - PubMed
-
- Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–1561. - PubMed
-
- Ariza X, Castellote J, Lora-Tamayo J, et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol. 2012;56:825–832. - PubMed
-
- Novovic S, Semb S, Olsen H, et al. First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage. Scand J Gastroenterol. 2012;47:212–216. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials